Alzamend Seeks to to Test AL001 as Dementia Therapy

Alzamend Seeks to to Test AL001 as Dementia Therapy

299163

Alzamend Seeks to to Test AL001 as Dementia Therapy

Alzamend Neuro has requested approval from the U.S. Food and Drug Administration (FDA) to begin clinical trials to test AL001, its investigational lithium-based ionic cocrystal oral therapy for dementia related to Alzheimer’s disease. The request was made in the form of an investigational new drug (IND) application that, if approved, will allow the start of Alzamend’s Phase 1 trial of AL001 evaluating AL001’s safety and appropriate dosing for future studies. “This IND submission represents a…

You must be logged in to read/download the full post.